Afghahi Targets Clinical Trial Bottlenecks With Tech

The Biomarker Bottleneck: Why Tests Drive Trial Success

Two days prior to the broader tech announcement, Afghahi focused specifically on the role of biomarker testing in a separate report published Monday.

Biomarkers are the biological signposts that tell researchers which patients are likely to respond to a specific therapy.

Without these tests, finding the right participant is like searching for a needle in a haystack.

The Monday report emphasizes that biomarker testing is the gateway to precision medicine trials, yet access remains uneven across the United States.

Patients in rural areas or those served by smaller health systems often face significant delays in getting necessary genomic profiling.

This creates a disparity in who gets into trials and who doesn't.

Afghahi points out that standardizing the ordering process for these tests through health technology can level the playing field.

When a biomarker test is ordered, the system should automatically flag relevant clinical trials for that patient's specific mutation or profile.

This removes the burden from the physician to manually search through trial registries.

• Biomarker tests unlock precision medicine.
• Access varies by geography and system size.
• Automated flags connect tests to trials instantly.

The cost of biomarker testing has historically been a barrier, but Afghahi notes that as sequencing prices drop, the logistical barrier becomes the primary hurdle.

Insurance coverage for these tests has improved, but the administrative workflow is often fractured.

Health technology platforms can now verify insurance coverage and pre-authorize biomarker testing within the same workflow that screens for trial eligibility.

This consolidation is crucial.

It means that by the time a patient's biomarker results come back, the clinical trial team has already been notified and can reach out immediately.

In oncology and cardiology, where Afghahi focuses, this speed can change treatment trajectories entirely.

The report argues that biomarker testing should no longer be seen as a diagnostic step alone, but as the first step of the clinical trial recruitment process.

Silicon Valley Meets Sickbay: How EHR Integration Works

The core of Afghahi's proposal relies on the interoperability of modern health systems.

For years, electronic health records were digital filing cabinets—useful for storage but terrible for active analysis.

That is changing.

New software layers sit on top of existing EHR systems, scanning patient data in real time against trial inclusion and exclusion criteria.

This process, often powered by natural language processing and machine learning, can read unstructured notes in a doctor's chart to find clues that structured codes miss.

For example, a patient might not have a specific code for 'heart failure with preserved ejection fraction,' but the doctor's notes might describe the symptoms and echocardiogram results that confirm it.

The technology catches this.

It then pings the research coordinator.

Officials in the health tech sector say this kind of automated matching reduces the 'screen failure' rate, where patients go through the trouble of signing up only to be disqualified later.

• EHR systems act as the data foundation.
• AI scans unstructured doctor notes for clues.
• Real-time matching reduces screen failures.

However, the implementation is not without challenges.

Data silos between major hospital systems mean that a patient who visits a specialist in one network might not be flagged if their primary care records are in another.

Afghahi's analysis calls for stronger data-sharing agreements and the adoption of FHIR (Fast Healthcare Interoperability Resources) standards.

These standards allow different systems to 'talk' to each other securely.

When these connections work, the impact is immediate.

A cardiologist treating a patient with a rare arrhythmia might be alerted to a trial for a new anticoagulant that they didn't even know existed.

This shifts the paradigm from patients finding trials to trials finding patients.

It transforms the physician from a passive observer into an active gatekeeper of research opportunities.

The High Cost of Empty Trial Slots

Why does this matter now?

The financial pressure on drug development is immense.

Bringing a new drug to market costs an estimated $2.6 billion, and a significant portion of that cost is attributed to running clinical trials that drag on for years.

Every day a trial seat remains empty is a day of lost revenue and a day patients go without hope.

Industry analysts note that the COVID-19 pandemic served as a massive accelerant for these technologies.

During the height of the pandemic, traditional site-based trials ground to a halt.

Researchers were forced to adopt decentralized trial models, using telemedicine, wearable devices, and remote monitoring.

Afghahi's work builds on this momentum, taking the lessons learned from the pandemic and applying them to chronic disease management.

The economic argument is compelling.

If health technology can cut the recruitment phase of a trial by just 20%, it can save a sponsor millions and bring a drug to market months earlier.

• Drug development costs exceed $2.6 billion.
• Pandemic accelerated decentralized trial adoption.
• Faster recruitment saves millions in operational costs.

But the human cost is higher.

For patients with terminal illnesses, clinical trials are often the last line of defense.

The current system is notoriously difficult to navigate.

Patients are expected to find their own trials on websites like ClinicalTrials.gov, understand complex medical eligibility criteria, and then ask their doctors to refer them.

Most give up.

Afghahi's vision is a system where the trial comes to the patient.

This 'push' model relies entirely on the robust health technology infrastructure he describes.

It requires a cultural shift in medicine as well, where research is viewed as a standard part of care rather than a specialized afterthought.

By embedding trial options into the daily workflow of clinicians, the stigma and mystery surrounding research participation dissipate.

Physician Burnout and the Administrative Burden

There is another, often overlooked, beneficiary of this technological shift: the doctors themselves.

Physician burnout is at an all-time high, driven largely by administrative workload and data entry.

Asking a busy oncologist or cardiologist to manually screen patients for trials is often a non-starter.

They simply do not have the time.

Afghahi's approach acknowledges this reality.

By automating the pre-screening process, the technology presents the physician with a 'curated list' of opportunities rather than a raw dump of data.

It does the heavy lifting.

Sources close to the implementation of these systems say that when done correctly, the technology feels like a decision support tool, not a chore.

One click is all it takes.

• Burnout limits manual screening efforts.
• Automation reduces administrative workload.
• One-click referrals streamline the process.

This efficiency is critical for the success of the trials Afghahi advocates for.

If the referral process is cumbersome, physicians will default to the standard of care, even if a trial might be better for the patient.

The Monday report on biomarker testing touches on this as well.

It suggests that when the ordering of a biomarker test is automatically linked to trial referral, it creates a 'nudge' for the physician.

It reminds them that research options exist.

This subtle integration is key.

It doesn't disrupt the doctor's workflow; it enhances it.

It turns the clinical encounter into a potential gateway for research without adding extra minutes to the visit.

As these technologies mature, experts predict we will see a rise in 'learning health systems,' where every patient interaction generates data that can inform future research, creating a continuous loop of improvement.

The Road Ahead: Regulatory Shifts and Patient Access

Looking forward, the success of this tech-driven model depends heavily on regulatory support and patient trust.

The Food and Drug Administration (FDA) has expressed strong support for decentralized trials and diverse enrollment strategies.

Afghahi's work aligns perfectly with these federal goals.

By leveraging technology to reach patients in community settings rather than just major academic medical centers, the industry can finally address the lack of diversity in clinical trial data.

Historically, trials have disproportionately enrolled white, male, urban patients.

This skews the data and limits the generalizability of the results.

Health technology that reaches into community clinics and rural health centers can democratize access.

• FDA supports decentralized trial models.
• Tech improves diversity in trial data.
• Community clinics gain access to cutting-edge research.

However, data privacy remains a top concern.

Sharing sensitive patient information between health systems and trial sponsors requires rigorous security protocols.

Afghahi emphasizes that any technological solution must prioritize patient consent and data security.

Patients need to know that their data is being used to help them, not exploit them.

The 'trust' factor is the final piece of the puzzle.

If patients trust that their doctor is recommending a trial because it is the best medical option, facilitated by a reliable system, they are more likely to enroll.

As the health care landscape continues to evolve, the integration of biomarker testing and digital enrollment tools represents the new frontier.

It moves the industry away from the slow, paper-based processes of the past toward a future where research and care are indistinguishable.

For patients waiting for a breakthrough, that future cannot arrive soon enough.

The technology is ready.

The question now is whether the infrastructure and the will exist to deploy it at scale.